AllianzIM U.S. Large Cap Buffer10 Sep ETF SEPT 深 滬
等待開盤 10-23 09:30:00 美东时间
34.34
-0.200
-0.58%
華盛通- 最 高34.67
- 今 開34.42
- 成交量 8735股
- 最 低 34.34
- 昨 收 34.54
- 總市值 1888.70万
- 52周最高 34.67
- 市盈率 靜 --
- 換手率 1.59%
- 52周最低 25.54
- 委 比 -47.19%
- 總股本 55.00万
- 歷史最高 34.67
- 量 比 1.53
- 振 幅 0.96%
- 歷史最低 23.42
- 每 手 1
- 風險率 1.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HUSQVARNA GROUP: INTERIM REPORT JANUARY - SEPTEMBER 2025
STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Third quarter 2025 Organic sales growth was flat. Net sales decreased by 5% to SEK 9,204m (9,739). Changes in exchange rates impacted by -5%. Operati...
10-21 13:28
T. ROWE PRICE GROUP REPORTS PRELIMINARY MONTH-END ASSETS UNDER MANAGEMENT FOR SEPTEMBER 2025
BALTIMORE, Oct. 10, 2025 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced preliminary September month-end assets under management of $1.77 trillion. Preliminary net outf...
10-10 20:30
ChipMOS REPORTS 10.5% YoY INCREASE IN SEPTEMBER 2025 REVENUE; 3Q25 REVENUE INCREASES 7.1% QoQ
HSINCHU, Oct. 9, 2025/PRNewswire-FirstCall/ -- ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourc...
10-09 18:00
Flywire Corporation (FLYW) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Sept. 19, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Flywire Corporation ("Flywire" or the "Company") (NASDAQ: FLYW) h...
09-20 03:51
TETRA TECHNOLOGIES, INC. INVESTOR DAY SCHEDULED ON SEPTEMBER 25, 2025, AT THE NEW YORK STOCK EXCHANGE
THE WOODLANDS, Texas, Sept. 17, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) will be hosting an Investor Day on Thursday, September 25, 2025, at 8:30AM...
09-18 03:52
Septerna to Participate in Upcoming Investor Conferences
Septerna, Inc., a clinical-stage biotech company focused on GPCR drug discovery, announced its participation in two upcoming investor conferences in September: the Cantor Global Healthcare Conference 2025 on September 3, 2025, and the 2025 Wells Fargo Healthcare Conference on September 5, 2025. Live webcasts and replays of the presentations will be available on the company’s website. Septerna specializes in advancing GPCR therapies using its prop...
08-27 12:00
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Septerna, Inc. has initiated a Phase 1 clinical trial for SEP-631, a novel oral treatment targeting chronic spontaneous urticaria and mast cell-driven diseases. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-631 in healthy volunteers. As a selective negative allosteric modulator of MRGPRX2, SEP-631 inhibits mast cell activation and degranulation, offering potential relief for millions affected b...
08-21 12:00
RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST) have opp...
08-15 00:00
Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) have oppo...
07-29 00:00
Septerna to Present at Jefferies Global Healthcare Conference
Septerna, Inc., a biotechnology company focused on GPCR drug discovery, announced that its CEO, Jeffrey Finer, will present at the Jefferies Global Healthcare Conference on June 5, 2025. A live webcast of the presentation will be available on the company’s website and will be archived for at least 30 days. Septerna’s proprietary Native Complex Platform™ enables the discovery of oral small molecule product candidates targeting endocrinology, immun...
05-29 12:00
